Maternal Diabetes and Early Neurodevelopment: Differential Risks Emerge Across Diabetes Types and Infant Sex
Posted inDiabetes & Endocrinology news Pediatrics

Maternal Diabetes and Early Neurodevelopment: Differential Risks Emerge Across Diabetes Types and Infant Sex

A nationwide cohort study of 466,462 infants reveals that maternal pregestational diabetes significantly increases the risk of delayed developmental milestones, with type 1 diabetes conferring the highest risk and female offspring showing particular vulnerability across language, personal-social, and gross motor domains.
Machine Learning Falls Short in Personalizing School-Based Mindfulness for Adolescent Depression Prevention: MYRIAD Trial Insights
Posted innews Pediatrics Psychiatry

Machine Learning Falls Short in Personalizing School-Based Mindfulness for Adolescent Depression Prevention: MYRIAD Trial Insights

Secondary analysis of the MYRIAD trial reveals that while machine learning models can identify adolescents who may benefit from school-based mindfulness training, the clinical relevance of such predictions remains minimal. Both causal forest and elastic net regression models detected statistically significant but practically trivial differences in outcomes.
TP53 Alterations Emerge as Critical Adverse Prognostic Factor in Pediatric and Young Adult Patients Treated with CD19-CAR T-Cell Therapy for Relapsed/Refractory B-ALL
Posted inHematology-Oncology news Pediatrics

TP53 Alterations Emerge as Critical Adverse Prognostic Factor in Pediatric and Young Adult Patients Treated with CD19-CAR T-Cell Therapy for Relapsed/Refractory B-ALL

A single-center retrospective study of 69 pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia reveals that TP53 alterations significantly compromise outcomes following tisagenlecleucel therapy. Patients harboring TP53 mutations or deletions demonstrated markedly lower remission rates and substantially worse event-free and overall survival compared to TP53 wild-type counterparts.
A New Standard for Pediatric Vocal Fold Immobility After Cardiac Surgery: Improving Outcomes Through Injection Laryngoplasty
Posted inCardiology news Otorhinolaryngology Pediatrics

A New Standard for Pediatric Vocal Fold Immobility After Cardiac Surgery: Improving Outcomes Through Injection Laryngoplasty

Recent research highlights a standardized multidisciplinary protocol for managing unilateral vocal fold immobility in infants after cardiothoracic surgery, showing that injection laryngoplasty significantly improves oral feeding advancement and reduces dependence on feeding tubes.
Beyond Height Velocity: Longitudinal Impact of Long-Acting Growth Hormone on Body Mass Index in Pediatric Growth Hormone Deficiency
Posted inClinical Updates Diabetes & Endocrinology news Pediatrics

Beyond Height Velocity: Longitudinal Impact of Long-Acting Growth Hormone on Body Mass Index in Pediatric Growth Hormone Deficiency

This meta-analysis reveals that long-acting growth hormone (LAGH) is associated with a significant increase in BMI SD scores during the first year of treatment and upon switching from daily GH, suggesting a distinct metabolic profile compared to daily regimens.
Misaligned Urgency: Why Status Exceptions May Be Paradoxically Lowering Priority for the Sickest Children in Heart Transplantation
Posted inCardiology news Pediatrics

Misaligned Urgency: Why Status Exceptions May Be Paradoxically Lowering Priority for the Sickest Children in Heart Transplantation

A large-scale analysis of 6,026 pediatric heart transplant candidates reveals that status exceptions often prioritize patients with lower mortality risk than those meeting standard criteria, highlighting a significant misalignment in the U.S. allocation system that the National Heart Review Board has yet to resolve.
Fordadistrogene Movaparvovec Fails to Improve Functional Outcomes in Duchenne Muscular Dystrophy: Insights from the Phase 3 CIFFREO Trial
Posted inNeurology news Pediatrics

Fordadistrogene Movaparvovec Fails to Improve Functional Outcomes in Duchenne Muscular Dystrophy: Insights from the Phase 3 CIFFREO Trial

The Phase 3 CIFFREO trial found that the gene therapy fordadistrogene movaparvovec did not significantly improve motor function in boys with Duchenne muscular dystrophy compared to placebo, leading to the discontinuation of its clinical development due to a negative benefit-risk profile.